Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters  by Locatelli, Francesco et al.
Kidney International, Vol. 50 (1996), pp. 1293—1302
Effects of different membranes and dialysis technologies on
patient treatment tolerance and nutritional parameters
FRANCESCO LOCATELLI, FRANCESCO MASTRANGELO, BRUNO REDAELLI, CLAUDIO RoNco,
DANIELE MARCELLI, GIUSEPPE LA GRECA, GIANCARLO ORLANDINI,
and the ITALIAN COOPERATIVE DIALYSIS STUDY GROUP'
Division of Nephrology and Dialysis, Ospedale di Lecco, Lecco; Division of Nephrology and Dialysis, Ospedale "Vito Fazzi", Lecce; Division of
Nephrology and Dialysis, Ospedale "S. Gerardo' Monza; Division of Nephrology and Dialysis, Ospedale "S Bortolo", Vicenza; and Medical Department,
Fresenius S. T., Palazzo Pignano, Italy
Effects of different membranes and dialysis technologies on patient
treatment tolerance and nutritional parameters. There is increasing
evidence that the biochemical and cellular phenomena induced by blood!
membrane/dialysate interactions contribute to dialysis-related intradiatytic
and long-term complications. However, there is a lack of large, prospec-
tive, randomized trials comparing biocompatible and bioincompatible
membranes, and convective and diffusive treatment modalities. The
primary aim of this prospective, randomized trial was to evaluate whether
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the use of polysulfone membrane with bicarbonate dialysate offers any
advantages (in terms of treatment tolerance, nutritional parameters and
pre-treatment f32-microglobulin levels) over a traditional membrane (Cu-
prophan®). A secondary aim was to assess whether the use of more
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sophisticated methods consisting of a biocompatible synthetic membrane
with different hydraulic permeability at different ultrafiltration rate (high-
flux hemodialysis and hemodiafiltration) offers any further advantages.
Seventy-one Centers were involved and stratified according to the avail-
ability of only the first two or all four of the following techniques:
Cuprophan® hemodialysis (Cu-HD), low-flux polysulfonc hemodialysis
(LfPS-HD), high-flux polysulfone high-flux hemodialysis (HfPS-HD), and
high-flux polysulfone hemodiafiltration (HfPS-HDF). The 380 eligible
patients were randomized to one of the two or four treatments (132 to
Cu-HD, 147 to LfPS-HD, 51 to HfPS-HD and 50 to HfPS-HDF). The
follow-up was 24 months. No statistical difference was observed in the
algebraic sum of the end points between bicarbonate dialysis with
Cuprophan® or with low-flux polysulfone, or among the four dialysis
methods under evaluation. There was a significant decrease in pre-dialysis
plasma 2-microglobulin levels in high-flux dialysis of 9.04 10.46 mg/liter(23%) and in hemodiafiltration of 6.35 12.28 mg/liter (16%), both using
high-flux polysulfone membrane in comparison with Cuprophan® and
low-flux polysulfone membranes (P = 0.032). The significant decrease in
pre-diatysis plasma 2-microglobulin levels could have a clinical impact
when one considers that 2-microglobulin accumulation and amyloidosis
are important long-term dialysis-related complications.
Survival, morbidity and the quality of life of uremic patients
undergoing regular hemodialytic treatment are still severely af-
fected by acute intradialytic and long-term complications possibly
related to the treatment itself. Cardiovascular instability is cer-
tainly the most important acute hemodialysis-related complica-
tion and malnutrition and f32-microglobulin deposition and con-
sequent amyloidosis [1, 2] are the most important long-term
complications.
The biocompatibility of dialysis membranes is increasingly
recognized as one of the main factors in the improvement of
dialytic treatment [31; moreover, convective treatment modalities,
such as hemodiafiltration and hemoflltration are thought to be
further improvements over standard diffusive hemodialysis [4].
However, there is a lack of large, prospective, randomized trials
comparing biocompatible and bioincompatible membranes, and
convective and diffusive treatment modalities. This problem has a
very important clinical and economic impact because of the
possible improvement in dialytic care and the higher cost of
biocompatible membranes and convective treatments. On the
other hand, there is the possibility that the recognized superiority
of biocompatible membranes on blood/membrane interaction
may be counterbalanced and even outweighed by blood/mem-
brane/dialysate interactions [5, 61.
The availability of low-flux polysulfone synthetic membrane has
made it possible to compare treatments that differ only in terms of
the chemical structures of the membranes themselves under
similar conditions of convective transport and permeability.
We therefore designed this multieenter, prospective random-
ized trial with the primary aim of evaluating whether the polysul-
fone membrane offers any advantages (in terms of treatment
tolerance, nutritional parameters and pre-treatment f32-micro-
globulin levels) over the traditional membrane (Cuprophan®) in
bicarbonate dialysis.
A secondary aim was to assess whether the use of more
sophisticated methods involving biocompatible synthetic mem-
branes with different hydraulic permeabilities (high-flux hemodi-
alysis and hemodiaflitration) offers any further advantages. The
reason for this further comparison was to evaluate the effect of
different levels of convection using membranes with the same
level of bicompatibility.
Methods
The participating Centers were divided into two strata. In the
first (41 Centers), the patients were randomly allocated to one of
two groups: Cuprophan® or low-flux polysulfone. In the second
(30 Centers), they were randomly allocated to one of four groups:
Cuprophan®, low-flux polysulfone, high-flux polysulfone high-
flux dialysis with highly convective transport or high-flux polysul-
fone hemodiafiltration (8 to 12 liter/session in post-dilution). The
dialysate was to be carefully handled to ensure its high quality and
prevent pyrogen back-transport from affecting the study results
[71
The planned duration of the follow-up was 12 months but, in
accordance with the protocol [81, this was extended by a further 12
months as the drop-out rate did not exceed 30% during the first
period.
Screening and baseline period
The following enrolment criteria were used: an age of 18 to 70
years, very stable clinical condition (in any case on renal replace-
ment therapy for no less than two months), and regular thrice-
weekly hemodialysis treatment. The exclusion criteria were the
presence of malignant disease (ascertained or suspected), myo-
cardial infarction within the previous 12 months, stroke or tran-
sient ischemic attacks within the previous six months, and severe
heart failure (NYHA III or IV).
Trial procedures
Visit —1 (start of run-in phase —1 month before initiating trial
treatment). The patients considered eligible for the trial on the
basis of the inclusion/exclusion criteria were given information
concerning the study and asked to give their informed consent.
Their date of birth, sex, underlying nephropathy, time on dialysis,
history of dialytic treatment, residual renal function, daily diuresis
and vascular access, together with the assigned code number and
type of treatment were recorded on special record forms. Their
existing dialytic schedule, and drugs (particularly any current
antihypertensive drugs, erythropoietin and iron supplement) were
maintained and recorded, as well as their pre- and post-dialysis
blood pressures, pulse rate and body wt, and the number of
symptomatic sessions.
Visit 0. A clinical examination, type I and II laboratory tests (see
below), 132-microglobulin, tricep and subscapular skinfold thick-
ness, mid-arm circumference, chest X-ray and electrocardiogra-
phy were performed. The randomly assigned dialytic treatment
was be started with the session time and blood flow being
scheduled in order to obtain a Kt/V  I and an ultrafiltration
rate < 2% body wt/hr. To obtain a Kt/V  1, the time was
adjusted according to the actual value obtained from the domain
map [9] and in vitro dialysis urea clearance (kDa urea) provided by
the manufacturer.
Maintenance period
Pre- and post-dialysis blood pressure, pulse rate and body wt
were recorded, as well as the details concerning all of the
symptomatic sessions. The programmed clinical and laboratory
tests (type 1, type 11 and f32-microglobulin) were carried out every
two and six months, respectively. Tricep and subscapular skinfold
thickness, and mid-arm circumference measurements, chest X-ray
and electrocardiography were performed every six months.
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Patient identification and treatment allocation
The admitted patients were randomly allocated to one of two or
four treatment groups (depending on the availability of treat-
ments in the Center). Three kinds of membrane [Cuprophan®
(Cu), low-flux polysulfone (LfPS), and high-flux polysulfone(HfPS)] were used for four kinds of treatment with only a
bicarbonate dialysate buffer: Cu hemodialysis (Cu-HD) LfPS
hemodialysis (LfPS-HD), HfPS high-flux hemodialysis (HfPS-
HD) and HfPS hemodiafiltration (HfPS-HDF). Randomization
was centralized at the Department of Ncphrology at Lecco
Hospital, using separate lists for each Center that were randomly
divided into blocks of four for the assignment of two or four
treatments (depending on the treatments available in the different
Centers). A 12-month recruitment period was estimated.
Clinical and laboratoiy measurements for safely and efficacy
Pre-dialytic systolic and diastolic blood pressure levels (Korot-
koff phase V) were measured after the patient had been lying in
the dialysis bed for five minutes; post-dialytic pressures were
measured in the same lying position, five minutes after the end of
the session. Body temperature (axillary) was measured at the start
and end of each dialysis session, and in the case of a pyrogenic
reaction. Tricep and subscapular skinfold thickness, and mid-arm
circumference were measured after the end of the mid-week
dialysis session (as far as possible by the same physician). The
adequacy of dialysis was evaluated by KtIV, estimated using the
Kt/V-PCR (protein catabolic rate) domain map 191, which re-
quires the measurement of steady-state mid-week pre- and post-
dialysis blood urea nitrogen (BUN) concentrations and is based
on therapy clearance only. The number of symptomatic sessions
was recorded for every month of follow-up. Type I laboratory tests
were: creatinine, urea, sodium, potassium, chloride, total and
ionized calcium, bicarbonate, sideremia, transferrin, ferritin, total
protein, albumin, hemoglobin, hematocrit, red blood cells, reticu-
locytes, leukocytes and platelets. Type II laboratory tests included:
uric acid, total cholesterol, triglycerides, glucose, bilirubin, AST,
ALT, alkaline phosphatase, PTH, yGT, HDL cholesterol.
Statistical analysis
Sample size. In view of the principal aim of the study, and the
limited possibility of enrollment for the four methods, the sample
size was calculated only for the groups treated with Cuprophan
(Cu-HD) and low-flux polysulfone (LfPS-HD) bicarbonate hemo-
dialysis both in the two and in the four randomized groups.
Furthermore, given the difficulty of taking into account all of the
planned end-points, this calculation was made only on the basis of
the expected improvement in tolerability. A sample size [101 of 80
subjects per group (Cu-HD and LIPS-HD) was presumed to allow
the detection of a reduction of up to 12% in the frequency of
symptomatic sessions (evaluated at about 30% with the standard
treatment) with a type 1 probability of error of 0.05 and a power
of 0.80. This number was increased to 115 subjects per group to
allow for an expected dropout rate of 30%.
Efficacy analysis. Efficacy was measured on the basis of the
evolution at 24 months of three parameters: treatment tolerance,
nutritional status and 2-microglobulin concentrations, using mul-
tiple end-point statistics according to Tang et al [11], because
there is no clear single end-point. Treatment tolerance and
nutritional status were combinations of other directly measurable
variables [the frequency of sessions with asymptomatic, symptom-
atic, and complicated hypotension (defined hypotension), and
body wt, tricep skinfold, mid-arm circumference, albuminemia,
transferrinemia and protein catabolic rate, respectively].
To avoid multiple testing bias, the three efficacy parameters of
the principal analysis were analyzed using a single test involving
the weighted means of their ranges [12, 13]. This analysis took into
consideration all of the patients with adequate small molecule
clearance (mean Kt/V  0.95). The evaluation was based on a
factorial analysis of variance for repeated measurements using the
results obtained at baseline, and after 6, 12, 18 and 24 months.
The statistical test used the following factors: the study treat-
ments, the level of the Centers' participation in the protocol
(randomization of 2 or 4 methods) and baseline treatments. The
principal analysis compared Cu-HD and LfPS-HD considering all
of the patients enrolled in the two groups (study A). A second
analysis compared all four methods, only considering those pa-
tients enrolled in the Centers where all four methods were
available (study B).
In the statistical analysis, comparisons were made between the
three alternative methods taken individually (LfPS-HD, HfPS-
HD, HfPS-HDF) and the reference method (Cu-HD); the other
comparisons included HfPS-HD versus LfPS-HD, HfPS-HDF
versus HfPS-HD, HIPS-HDF+HfPS-HD versus LfPS-HD+Cu-
HD, HfPS-HDF+HfPS-HD+LfPS-HD versus Cu-HD. All of
these comparisons were made using the Scheffé method [141.
Informed consent
Before starting the study, the subjects were informed about its
aims, the expected benefits to them and/or others, the risks and
inconveniences involved, as well as of their right to refuse to
participate or to withdraw from the study at any time without
sanction. Their oral informed consent was obtained.
Ethical surveillance. If a treatment was considered inadequate in
the judgement of the attending physician, the patient was trans-
ferred to the method that was most adequate for him/her. The
study was carried out in accordance with the Helsinki Declaration
and its subsequent modifications.
Results
Recruitment
Between May 1991 and November 1992, a total of 380 patients
were enrolled in the study, of whom 279 were randomly assigned
to Cuprophan® or low-flux polysulfone hemodialysis (study A,
175 patients in the Centers in which only these methods were
available and 104 in those offering all four methods), and 205 to
one of the four groups in the Centers offering all four methods
(study B, Cu-HD = 50, LfPS-HD = 54, HfPS-HD 51, HfPS-
1-IDF = 50; Table 1). The total number of patients assigned to
CuHD was 132 and to LfPS-HD 147.
Baseline patient characteristics
One hundred seventy-three of the 279 patients randomly as-
signed to Cu-RD or LfPS-HD were men (62.0%); the average age
was .54.0 12.7 years and the percentage of patients with diabetic
disease was 5.4%. One hundred forty-eight of the 205 patients
randomly assigned to one of the four treatment groups were men
(72.2%); the average age was 53.2 12.9 years and the percent-
age of patients with diabetic disease was 5.4%. The mean age,
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Table 1. Mean age, sex and percentage of diabetic patients in study A
(Cu-HD, LfPS-HD) and study B (Cu-HD, LfPSLJD, HfPS-HD, HfPS-
HDF)
Diabetic
Treatment
.Patients
N
Age
years
Male nephropathy
%
Study A
Cu-HD 132 53.6 12.7 63.6 4.5
LfPS-HD 147 54.4 12.8 60.5 6.1
Study B
Cu-HD 50 50.5 13.5 66.0 8.0
LfPS-HD 54 53.7 12.9 72.2 9.3
HfPS-HD 51 56.0 12.2 70.6 2.0
HfPS-HDF 50 52.7 12.9 80.0 2.0
gender and underlying diseases of the patients by treatment group
are shown in Table 1.
Follow-up
Of the 279 patients randomized to Cu-HD or LfPS-HD, 164
withdrew from the study during the two years of follow-up (Table
2): 20 for death, 22 for kidney transplant, 2 for acute clinical
reasons, 4 for fistula-related problems, 29 for treatment inade-
quacy and 89 for technical reasons.
Of the 205 patients randomized to one of the four treatment
groups, 97 withdrew from the study during the two years of
follow-up (Table 2): 13 for death, 24 for kidney transplant, 5 for
acute clinical reasons, 4 for fistula-related problems, 12 for
treatment inadequacy and 50 for technical reasons.
Treatment adequacy and protocol violators
For study A, the Kt/V values at baseline and during the
follow-up are described in Table 3. Two patients (0.7%) were
excluded from the statistical evaluation because their Kt/V was
lower than required; the frequency of protocol violators was not
different between the two treatments.
For study B, the Kt/V values at baseline and during the
follow-up in the four treatment groups are shown in Table 3. Four
patients (1.9%) were excluded from the statistical evaluation
because their Kt/V was lower than required; the frequency of
protocol violators was not different among the treatments.
Treatment tolerance
Treatment tolerance, evaluated as the sum of the monthly
number of dialysis sessions with hypotension, was 1.9 2.8
sessions/month for Cu-HD and 2.61 3.47 for LfPS-HD during
the run-in phase (P = NS). The behavior of this end-point during
the 24-month follow-up was not significantly different between
Cu-HD and LfPS-HD (Fig. 1).
In study B, the sum of the monthly number of dialysis sessions
with hypotension was 1.8 2.7 sessions/month for Cu-HD, 2.9
3.8 for LfPS-HD, 2.1 3.1 for HfPS-HD and 2.9 4.7 for
HfPS-HDF during the run-in phase (P = NS). The behavior of
this end-point during the 24-month follow-up was not significantly
different among the four treatment groups (Fig. 1).
Nutritional status
The baseline body wt of the patients assigned to Cu-HD was
61.6 12.3 kg and that of those assigned to LfPS-HD was 61.7
10.3 kg (P = NS). No differences were found in baseline sub-
scapular skinfold, triceps skinfold, mid-arm circumference,
plasma cholesterol or triglycerides (data not shown). Serum
albumin and serum transferrin at entry were respectively 4.2 0.4
g/dI and 236.0 66.1 mg/dl in the patients enrolled in the Cu-HD
group and 4.2 0.4 g/dl, and 242.5 66.0 mg/dl in those in the
LfPS-HD group. The baseline protein catabolic rate was 1.16
0.23 g/kg/day in the Cu-HD and 1.14 0.24 g/kg/day in the
LfPS-HD group. None of these variables was significantly differ-
ent between the two treatments at baseline. The behavior of
post-dialysis body wt (mean 24—0 months difference: 0.3 kg in the
Cu-HD and —0.1 kg in the LfPS-HD group), serum albumin
(mean 24—0 months difference: —0.22 g/dl in the Cu-HD and
—0.12 g/dl in the LfPS-HD group), serum transferrin values
(mean 24—0 months difference: —4 mg/dl in the Cu-HD and 0
mg/dl in the LfPS-HD group) are shown in Figures 2 to 4, and the
protein catabolic rate values in Table 3 (sub-scapular skinfold,
triceps skinfold, mid-arm circumference, plasma cholesterol and
triglycerides; data not shown). No statistical evidence was found
of any between-treatment differences in the behavior of any of
these variables during the 24-month follow-up.
In study B, the baseline body wt was 60.7 11.9 kg in the
patients in the Cu-HD group, and 62.8 10.9 kg in those in the
LfPS-HD, 63.7 10.5 kg in those in the HfPS-HD and 64.5 13.9
kg in those in the HfPS-HDF groups. No differences were found
in baseline sub-scapular skinfold, triceps skinfold, mid-arm cir-
cumference, plasma cholesterol or triglycerides (data not shown).
Serum albumin and serum transferrin at entry were respectively
4.2 0.3 g/dl and 222.8 50.2 mg/dl in the patients on Cu-HD,
4.2 0.4 g/dl and 227.0 56.3 mg/dl in those on LfPS-HD, 4.2
0.4 g/dl and 220.1 60.2 mg/dl in those on HfPS-HD and 4.1
0.5 g/dl and 240.5 70.1 mg/dl in those on HfPS-HDF. The
baseline protein catabolic rate was 1.10 0.19 g/kg/day in the
patients on Cu-HD, and 1.09 0.26, 1.21 0.27 and 1.18 0.22
glkg/day in those on LfPS-HD, HfPS-HD and HfPS-HDF, respec-
tively. There were no significant differences in any of these
variables at baseline among the four treatment groups. The
behavior of post-dialysis body wt (mean 24—0 months difference:
1.3, —0.2, —1.6 and —1.0 kg in the Cu-HD, LfPS-HD, HfPS-HD
and HfPS-HDF groups, respectively), serum albumin (mean 24—0
months difference: —0.20, —0.14, —0.11 and —0.15 g/dl in the
Cu-HD, LfPS-HD, HfPS-HD and HfPS-HDF groups, respective-
ly), serum transferrin (mean 24—0 months difference: 1, 15, —3
and 5 mg/dl in the Cu-HD, LfPS-HD, HfPS-HD and HfPS-HDF
groups, respectively) and protein catabolic rate are shown in
Figures 2 to 4 and Table 3 (data not shown for sub-scapular
skinfold, triceps skinfold, mid-arm circumference, plasma choles-
terol and triglycerides). No statistical evidence was found of any
between-treatment differences in the behavior of any of these
variables.
/32-micro globulin
Plasma /32-microglobulin levels were measured before the
mid-week dialysis session. The baseline values were 40.4 16.2
and 36.9 13.2 mg/liter in the patients on Cu-HD and LfPS-HD,
respectively (P = NS). There were no between-treatment differ-
ences in the behavior of this variable (Fig. 5) during the 24-month
follow-up. Baseline median creatinine clearance was 0.0 mI/mm in
the study A population as a whole, with no differences between
the two groups; the same was also true for the behavior of
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Table 2. Drop-outs by study and dialysis treatment
Technical
reasons
Acute Clinical
reason Fistula-related
Treatment
inadequacy Transplant Death Total
Study A
Cu-HD 42 1 1 13 13 8 76
LfPS-HD 47 1 3 16 9 12 88
Total 89 2 4 29 22 20 164
Study B
Cu-HD 12 1 1 3 6 2 25
LfPS-HD 13 1 2 4 4 3 27
HfPS-HD 13 3 1 2 6 1 26
HfPS-HDF 12 0 0 3 8 7 30
Total 50 5 4 12 24 13 97
creatinine clearance during the 24-month follow-up (data not
shown).
In study B, the baseline plasma f32-microglobulin levels were
44.7 17.7, 37.7 13.5, 39.9 13.7 and 36.0 13.7 mg/liter in
the patients on Cu-HD, LfPS-HD, HfPS-HD and HfPS-HDF,
respectively (P = NS). The behavior of this variable was signifi-
cantly different in the four treatment groups during the 24-month
follow-up (P = 0.032; Fig. 3). There were no changes in the
patients randomly assigned to Cuprophan® or low-flux polysul-
fone membrane dialysis (from 44.7 17.7 mg/liter to 40.6 14.8
mg/liter and from 37.7 13.5 mg/liter to 43.4 9.6 mg/liter,
respectively), hut there was a significant decrease in those on
high-flux dialysis (from 39.9 13.7 mg/liter to 28.8 14.2
mg/liter) and hemodiafiltration with the high-flux polysulfone
membrane (from 36.0 13.7 mg/liter to 32.2 14.2 mg/liter).
Baseline median creatinine clearance was 0.0 mI/mm in the study
B population as a whole, with no differences among the four
groups; the same was also true for the behavior of residual renal
function during the 24-month follow-up (data not shown).
Morbidity and mortality
There were no significant differences in mortality between the
two treatment groups in study A as evaluated by survival curves
(the 24-month cumulative survival was 82% in the Cu-HD and
88% in the LfPS-HD group), nor in the number of hospital
admissions per year (0.4 0.8 vs. 0.5 1.2, respectively), nor in
the number of days per year spent in the hospital (4.0 10.0 vs.
4.7 11.5, respectively).
In study B, there were no significant differences in mortality
among the four treatment groups as evaluated by survival curves
(the 24-month cumulative survival was 94, 93, 97, 81% in the
patients on Cu-HD, LfPS-HD, HfPS-HD, HfPS-HDF, respective-
ly), nor in the number of hospital admissions per year (0.4 0.9,
0.3 0.6, 0.1 0.2 and 0.3 0.6, respectively), nor in the number
of days per year spent in hospital (4.7 11.50, 4.2 14.2, 1.3
4.4 and 3.6 8.2, respectively).
Efficacy analysis
After two years of follow-up, the efficacy analysis (which takes
baseline treatment and participation level into account as prog-
nostic variables) revealed no statistical differences between stan-
dard bicarbonate hemodialysis with Cuprophan® or polysulfone.
The efficacy analysis related to the four randomized groups
(which takes baseline treatment into account as a prognostic
variable) revealed no statistical differences between standard
bicarbonate hcmodialysis with Cuprophan® and low-flux polysul-
fone, high-flux hemodialysis and hemodiafiltration with high-flux
polysulfone.
Univariate descriptive analysis showed that were no conflicting
trends in the behavior of any single variable related to any single
end-point (Figs. 1 to 4 and Table 3).
Table 3. Behaviour of Kt/V and protein catabolic rate (PRC) at baseline and during follow-up in study A and study B (mean and so)
Treatment
Study A
Variable Run-in 6 months 12 months 18 months 24 months
Cu-HD Kt/V
PCR
LfPS-HD Kt/V
PCR
Study B
Cu-HD
LfPS-HD
HfPS-HD
HfPS-HDF
1.27 0.28 1.27 0.26 1.34 0.23 1.30 0.22 1.32 0.20
1.16 0.23 1.18 0.23 1.21 0.22 1.21 0.25 1.24 0.24
1.24 0.23 1.30 0.21 1.34 0.25 1.35 0.29 1.35 0.25
1.14 0.24 1.17 0.25 1.21 0.24 1.21 0.30 1.22 0.24
Kt/V 1.27 0.25 1.29 0.23 1.32 0.25 1.27 0.18 1.30 0.20
PCR 1.10 0.19 1.12 0.22 1.13 0.18 1.12 0.23 1.22 0.21
Kt/V 1.21 0.27 1.27 0.20 1.28 0.26 1.34 0.25 1.31 0.21
PCR 1.09 0.26 1.11 0.24 1.12 0.22 1.16 0.36 1.17 0.21
Kt/V 1.26 0.28 1.34 0.24 1.32 0.24 1.38 0.25 1.31 0.20
PCR 1.21 0.27 1.20 0.22 1.12 0.24 1.18 0.26 1.19 0.22
Kt/V 1.30 0.23 1.41 0.24 1.31 0.15 1.37 0.27 1.47 0.18
PCR 1.18 0.22 1.18 0.22 .12 0.23 1.14 0.22 1.26 0.26
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Discussion
There is a body of evidence that blood/membrane interactions
cause a number of adverse biological reactions mainly affecting
the immune system, with consequent protein catabolism, and a
susceptibility to malnutrition, infections and malignancies [3, 15,
161. These events could affect intradialytic cardiovascular stability
and the long-term morbidity and mortality of dialyzed uremic
patients. On the other hand, the importance of dialysate quality is
increasingly recognized as a possible hazard caused by the back-
transport of pyrogens and endotoxin fragments into the blood-
stream [5, 61. Strangely enough, very few prospective, randomized
and controlled trials have addressed the issue of the clinical
relevance of the biological derangement caused by blood-mem-
brane interactions [17—201.
We therefore performed this prospective, randomized con-
trolled trial in which treatments using membranes with a high and
low level of biocompatibility were compared at the same level of
convection, and treatments with different convection rates were
compared using membranes with the same level of biocompatibil-
ity. Moreover, treatment with a low level of biocompatibility and
a low convection rate was compared with highly biocompatible
treatments given at different convection rates.
The percentage of intradialytic hypotension (asymptomatic,
symptomatic or complicated) was low at baseline, irrespective of
the patient group; this was maintained during the 24-month
follow-up. The incidence of intradialytic hypotension was 14 to
22% of the dialysis sessions, as against an expected percentage of
30%, with no differences between the two or four randomized
treatments. This may be due to a bias in selecting the patients
admitted to the study, even though the exclusion criteria were not
very strict. The mean age of the trial population was 54.1 years old
and the percentage of diabetic patients was 5.4% versus a mean
age of 59 years in the Italian dialytic population as a whole in the
same year with a percentage of diabetic patients of about 6.5%.
Another possibility could be the improved medical care typical of
controlled clinical trials and the good quality of standard dialytic
medical care in Italy [21]. These results are in agreement with
those of the Bergamo Collaborative Dialysis Group [181, which
evaluated acute intradialytic well-being.
We would like to stress that it is very difficult to find any
differences in the percentage incidence of intradialytic hypoten-
sion among membranes and treatment modalities if the incidence
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Fig. 1. Sum of monthly number of dialysis sessions with non-symptomatic
hypotension, symptomatic hypotension and complicated hypotension at
baseline and during follow-up in study A (A) and study B (B) (mean and SE).
Symbols are: (—) Cu-HD; (----) LfPS-HD; () HfPS-HD; (_ —— —)
HfPS-HDF.
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Fig. 2. Changes in post-dialysis body wt in respect to baseline in study A
(A) and study B (B) (mean). Symbols are: (—) Cu-HD; (----) LfPS-HD;(..) HfPS-HD; (... — —) HfPS-HDF.
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is low. In any case, the use of high-flux biocompatible membranes
in daily clinical practice in a trial with a total of 380 patients
enrolled in 71 centers (101 patients randomized to the high-flux
membrane) did not lead to any clinically relevant incidence of
pyrogenic reactions.
The same considerations can also be applied to the nutritional
evaluation because one of the inclusion criteria was a protein
catabolic rate of no less than 1 g/kglday. The levels of plasma
albumin were well preserved in the population as a whole at
baseline (4.16 gIdl), particularly when we consider that the mean
dialytic age of our patients was 58 months. No significantly
different behavior in the clinical and biochemical nutritional
parameters was found among the four randomized patient groups
during the 24 month study follow-up. These results conflict with
the data from a recent study by Parker et al [19], which show an
increase in estimated dry body wt (about 4 kg) and albumin (about
0.35 mgldl) in patients treated for 18 months with low-flux
biocompatible membranes. A possible explanation of this differ-
ence could be the higher baseline plasma albumin levels in our
patients, and the fact that the patients involved in Parker et al's
study were all at the start of renal replacement therapy {19J.
Moreover, the presence of smoldering overhydratation in the
patients treated with biocompatible membrane cannot be cx-
eluded. Finally, the very high number of dropouts due to treat-
ment inadequacy in the group of patients on the biocompatible
membrane (32%) in comparison with those on the bioincompat-
ible membrane (5%) of Parker et al's study [19] is another
possible reason for the different results.
Our trial was not designed to evaluate the relationship between
KtIV and protein catabolic rate. Kt/V was at protocol-suggested
values at baseline and further increased during follow-up, with no
difference in behavior being observed in the four randomized
patient groups. However, no relationship was found between KtIV
and protein catabolic rate as an index of protein intake. Thus, the
results of this study do not support the previously suggested
relationship between Kt/V and PCR [22], or the possibility of
obtaining higher protein catabolic rates at the same levels of Kt/V
using biocompatible membranes (at least not in the range of KtIV
and PCR values foreseen by our protocol). A possible reason for
this lack of correlation may be the high levels of KtIV recorded in
our patients. Considering a curvilinear relationship between PCR
and Kt/V, our patients probably fall into the plateau region where
a steep correlation between efficiency and nutrition is lost.
The high cumulative 24-month survival and low hospitalization
rate of the patients in this study (with no differences among the
four randomized patient groups) are not unexpected findings if we
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Fig. 4. Serum transferrin at baseline and during follow-up in study A (A)
and study B (B) (mean and SE). Symbols are: (—) Cu-HD; (.---)
LfPS-HD; (_) HfPS-HD; (... — — —) HfPS-HDF.
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Fig. 3. Serum albumin at baseline and during follow-up in study A (A) and
study B (B) (mean and SE). Symbols are: (—) Cu-HD; (----) LfPS-HD;
(__.) HfPS-HD; (... — — —) HfPS-HDF.
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take into account our previous considerations concerning cardio-
vascular stability and nutrition. These results are in agreement
with the findings of Collins et al [20] and Martin Malo and Castillo
[23]. Future trials should be designed involving a sicker patient
population with a high prevalence of intradialytic hypotension and
malnutrition in order to provide statistical power.
We were also unable to confirm Vanholder et al's observation
(in a study involving 16 patients with a 20-week follow-up [24]) of
a reduction in the number of episodes of sepsis in patients treated
with polysulfone versus those treated with Cuprophan® mem-
branes. The possibility of a lower rate of mortality due to infection
being achieved with the use of semisynthetic or synthetic mem-
branes has recently been reported in a USRDS Case Mix Ade-
quacy Study analysis by Bloembergen et al [25]. In this regard, the
benefits of using biocompatible membranes in terms of recovery
from acute renal failure, survival and a reduction in infections are
very impressive in the only two prospective randomized trials
comparing Cuprophan® with biocompatible synthetic membranes
[26, 271, although some criticisms have been raised [28, 29]. We
would like to underline the fact that a number of non-randomized
retrospective studies [25, 30, 31], many of which have only been
published in abstract form, have reported a reduction in mortality
of from 15 to 20% to 9 to 11% when patients on standard dialysis
with a cellulose membrane are compared with those on high-flux
hemodialysis with a biocompatible membrane. Therefore, as is
usual in medicine, the results of retrospective studies must be
carefully analyzed because the potential for residual confounding
by unmeasured factors cannot be entirely excluded, even if
sophisticated statistical methods are used [25, 311.
The last aspect is the important one of 2-microglobulin
dialytic-related amyloidosis [2, 32]. No relationship between pre-
dialysis plasma p2-microglobulin levels and dialysis-related amy-
loidosis was found [33]. However, it is difficult to find other
parameters suitable for large-sized clinical trials because sophis-
ticated evaluation methods should be reserved for smaller kinetic
studies and the in-depth evaluation of some aspects of /32-
microglobulin deposition [34]. We found a significant decrease in
pre-dialysis plasma 32-microglobulin levels with both high-flux
hemodialysis and hemodiafiltration using high-flux polysulfone.
The extent of the phenomenon was considerable (23% and 16%.
respectively). However, no difference was found between the
Cuphrophan® and low-flux polysulfone membranes. These data
cannot be explained by any difference in residual renal function
among the four randomized patient groups, which was in any case
very low even at baseline in the population as a whole. Our trial
was designed with the aim of separately detecting the effects of
biocompatibility and permeability of the membrane, and its
results favor the effect of the removal of f32-microglobulin by
convection or absorption over the possibility of a lower rate of
production due to biocompatibility. These data are not in agree-
ment with the results of Hakim et al [35], who found that a
low-flux biocompatible membrane (Polymethylmetacrylate) in
comparison with a bioincompatible membrane prevented a signif-
icant increase in plasma /32-microglobulin levels in patients at the
beginning of the dialysis treatment for the 18 months of follow-up.
The findings of our study relating to pre-dialysis plasma /32-
microglobulin levels are very important because of their possible
clinical impact. It is worth noting that a much higher prevalence of
amyloidotic 132-microglobulin deposits in the periosteum of the
iliac crest have been found in chronic hemodialyzed patients with
femoral neck fractures [36], further supporting the clinical rele-
vance of the problem. Moreover, it is well known that carpal
tunnel syndrome and p2-microglobulin dialysis-related amyloid-
otic arthropathy are present in a very large percentage of espe-
cially older patients on long-term regular dialytic treatment, and
that this greatly affects their quality of life [37]. Van Ypersele de
Strihou et at [38] retrospectively analyzed patients treated with
different membranes and found a lower incidence of cystic bone
lesions in patients treated with a synthetic membrane (AN69)
than in those treated with a Cuprophan® membrane. However,
some other retrospective studies have not found any differences in
term of p7-microglobulin related morbidity [39, 40]. All that we
can say is that the present standard dialytic treatment (diffusive
Cuprophan® dialysis) is incapable of preventing these disabling
uremic complications.
In conclusion, the results of this study of a large trial population
clearly demonstrate the feasibility and safety of the use of not only
hemodiafiltration, hut also high-flux hemodialysis with high-flux
biocompatible polysulfone membranes. The incidence of intradia-
lytic hypotension in the population as a whole was less than
expected, possibly because of a selection bias and/or good medical
care; in this stable uremic population, we were unable to find any
difference in cardiovascular stability in the four randomized
groups treated with membranes of different biocompatihilities and
-
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Fig. 5. Mid-weekpre-dialysis plasma /32-microglobulin levels at baseline and
during follow-up in study A (A) and study B (B) (mean and SE). Symbols are:
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at different convective ultrafiltration rates. It is important to
underline the fact that, when there is no difference between
treatment groups, one does not accept the null hypothesis but
rather fails to reject it, In other words, if the data do not show any
between-treatment difference, this does not imply equivalence but
rather that there is not enough evidence to conclude that one
treatment is better than the others. In our study, it simply means
that the sample size was too small to detect a difference in the
percentage incidence of intradialytic hypotension of less than the
stated 12% with a power of 80%. The same is also true for the
nutritional status of the patients, as evaluated both clinically and
biochemically. We did not find any difference in mortality and
morbidity among the four randomized patient groups during the
24-month follow-up, but the observation period did not allow any
evaluation of a possible difference in long-term morbidity and
mortality. Therefore, future trials should involve a sicker patient
population with a high prevalence of intradialytic hypotension and
malnutrition in order to achieve statistical power, although such
evaluations are very difficult because of the high patient drop-out
rate in long-term randomized trials.
A significant decrease in pre-dialysis plasma f32-microglobulin
levels was found in the patients randomly assigned to high-flux
hemodialysis and hemodiafiltration with biocompatible high-flux
polysulfone membranes, in comparison with those treated with
low flux-polysulfone or Cuprophan® membranes. These findings
could have a very important clinical impact [41], bearing in mind
that dialysis-related amyloidosis is one of the most important
issues in long-term hemodialysis treatment (especially in the older
patients currently being managed) and greatly affects the patient's
quality of life.
Reprint requests to Prof Francesco Locatelli, M.D., Divisione di Nefrologia
e Dialisi, Ospedale di Lecco, via Ghislanzoni 22, 22053 Lecco, Italy.
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